Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

What's a Realistic Retirement Budget? I'm 55 With $620k Saved and $68k Income

View original at finance.yahoo.com
What's a Realistic Retirement Budget? I'm 55 With $620k Saved and $68k Income There are two common ways to think about a retirement budget: you can start with the lifestyle you want or the assets you have…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Social Security defines full retirement age as 67, when most people can first claim unreduced benefits

    80% confidence
  • Claiming Social Security at 62 can lower payments to roughly 70% of the full amount

    80% confidence
  • Delaying Social Security benefits to age 70 can reach about 124% of the full retirement age amount

    80% confidence
  • A 55-year-old with $620,000 in a 401(k) earning $68,000 per year and contributing 10% annually could reach about $1.69 million by age 67

    80% confidence
  • Using the 4% rule, if your goal is to withdraw $100,000 annually in retirement income your savings target would be roughly $2.5 million

    80% confidence
  • Earlier retirement generally increases exposure to inflation and longevity risk

    80% confidence
  • Some analysts note that current bond yields and market conditions may support different withdrawal assumptions than the 4% rule

    80% confidence
  • Savings held in a Roth account generally allow qualified withdrawals to be tax-free

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com